Generalized Myasthenia Gravis (gMG)
Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UP
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
UCB PharmaZilucoplan®
Cabaletta BioCABA-201
Clinical Trials (2)
Total enrollment: 27 patients across 2 trials
Zilucoplan for Severe gMG Exacerbations
Start: Jan 2026Est. completion: Apr 202815 patients
Phase 3Recruiting
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Start: Dec 2024Est. completion: Sep 202912 patients
Phase 1/2Active Not Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
9h ago
Director of Finance
CoMind
London, UK
9h ago
Electronics Engineering Manager
CoMind
London, UK
9h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 27 patients
2 companies competing in this space